A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
Study of Remdesivir in Participants Hospitalized with Moderate COVID-19
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAS9654
U.S. Govt. ID: NCT04292730
Contact: Allison Wolf: 212-342-4412 / aw2565@cumc.columbia.edu
Additional Study Information: There are no approved medications to treat COVID-19, a new disease caused by a virus called SARS-CoV-2 that was just identified in late 2019. Some people who become sick with COVID-19 develop a very serious disease. The purpose of this study is to see if Remdesivir (RDV) can improve your health from being sick with COVID-19 infection. The other purpose of this study is to test if RDV is safe and tolerated by people with moderate COVID-19. We will find out all these things, and also how long it stays in your body, using physical exams, laboratory tests, and any symptoms or problems you might experience during the study.
This study is closed
Investigator
Max O'Donnell, MD, MPH
Do You Qualify?
Is the patient 12 years of age or older? Yes No
Has the patient tested positive for COVID-19? Yes No
Is the patient currently hospitalized and requiring medical care for COVID-19? Yes No
Does the patient currently require mechanical ventilation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Allison Wolf
aw2565@cumc.columbia.edu
212-342-4412
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE